Investigational dopamine antagonists for the treatment of schizophrenia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, Sheng-Min | - |
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Lee, Soo-Jung | - |
dc.contributor.author | Jun, Tae-Youn | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Masand, Prakash S. | - |
dc.contributor.author | Pae, Chi-Un | - |
dc.date.accessioned | 2021-09-03T14:58:42Z | - |
dc.date.available | 2021-09-03T14:58:42Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1354-3784 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/86303 | - |
dc.description.abstract | Introduction: Schizophrenia is a debilitating illness with a chronic impact on social function and daily living. Although various antipsychotics are available, there are still many challenges and unmet needs. Thus, many compounds with diverse mechanisms have been investigated, but all approved antipsychotics still require interactions with dopamine D-2 receptors.Areas covered: We searched for investigational drugs using the key words dopamine' and schizophrenia' in American and European clinical trial registers (clinicaltrials.gov; clinicaltrialsregister.eu). Published articles were searched in PubMed, Embase, Medline, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Web of Science and the Cochrane Central Register of Controlled Trials Library.Expert opinion: The prospect of developing a dopamine antagonist is hopeful. Brexpiprazole and cariprazine, which were agents listed as investigational dopamine antagonists,' just received FDA approval. Novel agents such as BL 1020, ITI-007, and JNJ-37822681 have solid published data available, and agents such as L-THP, Lu AF35700, S33138, and SB-773812 are under vigorous investigation. However, the expected benefits of the newly developed antagonists may not be great because they offer little enhanced efficacy for negative symptoms, cognition and functional outcomes. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject | D-2 RECEPTOR ANTAGONIST | - |
dc.subject | ATYPICAL ANTIPSYCHOTICS | - |
dc.subject | L-TETRAHYDROPALMATINE | - |
dc.subject | D3 RECEPTOR | - |
dc.subject | COGNITIVE IMPAIRMENT | - |
dc.subject | CLINICAL DEVELOPMENT | - |
dc.subject | PREFRONTAL CORTEX | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | DRUGS | - |
dc.subject | HYPOTHESIS | - |
dc.title | Investigational dopamine antagonists for the treatment of schizophrenia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.identifier.doi | 10.1080/13543784.2017.1323870 | - |
dc.identifier.scopusid | 2-s2.0-85019961335 | - |
dc.identifier.wosid | 000401712800004 | - |
dc.identifier.bibliographicCitation | EXPERT OPINION ON INVESTIGATIONAL DRUGS, v.26, no.6, pp.687 - 698 | - |
dc.relation.isPartOf | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - |
dc.citation.title | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - |
dc.citation.volume | 26 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 687 | - |
dc.citation.endPage | 698 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | D-2 RECEPTOR ANTAGONIST | - |
dc.subject.keywordPlus | ATYPICAL ANTIPSYCHOTICS | - |
dc.subject.keywordPlus | L-TETRAHYDROPALMATINE | - |
dc.subject.keywordPlus | D3 RECEPTOR | - |
dc.subject.keywordPlus | COGNITIVE IMPAIRMENT | - |
dc.subject.keywordPlus | CLINICAL DEVELOPMENT | - |
dc.subject.keywordPlus | PREFRONTAL CORTEX | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | DRUGS | - |
dc.subject.keywordPlus | HYPOTHESIS | - |
dc.subject.keywordAuthor | Schizophrenia | - |
dc.subject.keywordAuthor | Investigational antipsychotics | - |
dc.subject.keywordAuthor | Phase II | - |
dc.subject.keywordAuthor | agonist | - |
dc.subject.keywordAuthor | antagonist | - |
dc.subject.keywordAuthor | dopamine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.